Related Experiment Video
Updated: Jun 11, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Helen Ling1, Sean S O'Sullivan, Janice L Holton
1Reta Lila Weston Institute of Neurological Studies, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK.
Brain : a Journal of Neurology
|June 30, 2010
Summary
Corticobasal degeneration (CBD) is often misdiagnosed, with low sensitivity and positive predictive value in clinical settings. Recognizing its broader clinical spectrum is crucial for accurate diagnosis of this distinct neurological disorder.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Corticobasal degeneration (CBD) presents with diverse clinical syndromes, and corticobasal syndrome (CBS) is associated with various pathologies.
- Diagnostic challenges exist in differentiating CBD from other neurodegenerative conditions.
Purpose of the Study:
- To identify diagnostic pitfalls in corticobasal degeneration and corticobasal syndrome.
- To evaluate the accuracy of clinical diagnoses against pathological findings.
Main Methods:
- Archival case review of patients with clinical diagnosis of CBS or pathological diagnosis of CBD over 20 years.
- Analysis of diagnostic sensitivity, specificity, and predictive values.
Main Results:
- Only 26.3% of pathologically confirmed CBD cases were correctly diagnosed during life.
- 23.8% of clinically diagnosed CBS cases had confirmed CBD pathology; many had other neurodegenerative diseases.
- CBD can mimic progressive supranuclear palsy (PSP), leading to misdiagnosis.
Conclusions:
- Corticobasal degeneration is a distinct clinicopathological entity with a wider clinical spectrum than previously recognized.
- Improved diagnostic criteria are needed to address the significant overlap and misdiagnosis between CBD and PSP.
Related Concept Videos
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
01:19Cushing Syndrome II: Pathophysiology
Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...